3.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.97
Aprire:
$3.795
Volume 24 ore:
43.30M
Relative Volume:
2.75
Capitalizzazione di mercato:
$1.10B
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.9701
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
+40.60%
1M Prestazione:
+75.00%
6M Prestazione:
-47.36%
1 anno Prestazione:
-63.96%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
3.29 | 1.33B | 32.77M | -440.22M | -400.48M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-15 | Downgrade | Goldman | Neutral → Sell |
2025-05-16 | Downgrade | UBS | Buy → Neutral |
2025-05-12 | Downgrade | Truist | Buy → Hold |
2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-10-24 | Iniziato | UBS | Buy |
2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-11-20 | Iniziato | Goldman | Buy |
2023-09-18 | Reiterato | Barclays | Overweight |
2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-12-09 | Downgrade | Goldman | Buy → Neutral |
2022-10-31 | Iniziato | Guggenheim | Neutral |
2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
2021-12-07 | Ripresa | Cowen | Outperform |
2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2021-05-19 | Downgrade | Stifel | Buy → Hold |
2021-05-03 | Iniziato | Truist | Buy |
2021-04-16 | Iniziato | Goldman | Buy |
2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-04-22 | Iniziato | Mizuho | Buy |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-02-26 | Reiterato | H.C. Wainwright | Buy |
2020-02-26 | Reiterato | Oppenheimer | Outperform |
2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
2019-10-01 | Iniziato | Stifel | Buy |
2019-04-29 | Iniziato | Piper Jaffray | Overweight |
2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
2019-02-07 | Iniziato | Robert W. Baird | Outperform |
2018-12-31 | Ripresa | B. Riley FBR | Buy |
2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
2018-01-25 | Reiterato | H.C. Wainwright | Buy |
2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World
Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative
Here’s why Iova stock surged 32% today and why the rally might not be over - TradingView
Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest
Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade
Positive Week for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Institutional Investors Who Lost 64% Over the Past Year - 富途牛牛
Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com
Where are the Opportunities in (IOVA) - news.stocktradersdaily.com
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - The Motley Fool
Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - PrintWeekIndia
Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World
What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com
Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade
Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com
Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade
Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener
Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada
Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada
Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com
Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail
IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest
Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):